Osimertinib in EGFR Mutation-Positive Advanced NSCLC

被引：25
|
作者：
不详
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 13期
关键词：
PARAGANGLIOMA;
D O I：
10.1056/NEJMc1801669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1260 / 1261
页数：2
相关论文
共 50 条
  • [31] Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
    Maximilian J. Hochmair
    Anna Buder
    Sophia Schwab
    Otto C. Burghuber
    Helmut Prosch
    Wolfgang Hilbe
    Agnieszka Cseh
    Richard Fritz
    Martin Filipits
    Targeted Oncology, 2019, 14 : 75 - 83
  • [32] Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
    Hochmair, Maximilian J.
    Buder, Anna
    Schwab, Sophia
    Burghuber, Otto C.
    Prosch, Helmut
    Hilbe, Wolfgang
    Cseh, Agnieszka
    Fritz, Richard
    Filipits, Martin
    TARGETED ONCOLOGY, 2019, 14 (01) : 75 - 83
  • [33] Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
    Ramalingam, S.
    Yang, J. C. -H.
    Lee, C. K.
    Kurata, T.
    Kim, D. -W.
    John, T.
    Nogami, N.
    Ohe, Y.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S152 - S152
  • [34] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schmid, S.
    Schar, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L.
    von Briel, T.
    Waibel, C.
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W. D.
    Siano, M.
    Boos, L.
    Britschgi, C.
    Fruh, M.
    LUNG CANCER, 2024, 187
  • [35] Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
    Santos, Edgardo S.
    Kaplan, Barry
    Kirshner, Eli
    Croft, Elisabeth F.
    Sequist, Lecia, V
    Chau, MyDoanh
    Munley, Jiefen
    Oxnard, Geoffrey R.
    ONCOLOGY AND THERAPY, 2018, 6 (01) : 45 - 58
  • [36] Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation-Positive Lung Cancer Cells
    Skupin-Mrugalska, Paulina
    Minko, Tamara
    PHARMACEUTICS, 2020, 12 (10) : 1 - 17
  • [37] Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
    Edgardo S. Santos
    Barry Kaplan
    Eli Kirshner
    Elisabeth F. Croft
    Lecia V. Sequist
    MyDoanh Chau
    Jiefen Munley
    Geoffrey R. Oxnard
    Oncology and Therapy, 2018, 6 (1) : 45 - 58
  • [38] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [39] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Pan, Jie
    Cai, Xiaoping
    Cao, Zhuo
    Pan, Jiongwei
    Zheng, Hao
    PHARMACOLOGY, 2023, 108 (01) : 8 - 16
  • [40] NSCLC with EGFR-Mutation: Benefits of Osimertinib
    Brueckl, Wolfgang M.
    Ficker, Joachim H.
    PNEUMOLOGIE, 2020, 74 (12): : 803 - 804
12345